Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Choksi AsiaBOM:530427 +1.56%52 Return-on-Tangible-Equity is 9.17% as of Mar. 2026, which is 49% above its 10-year median of 6.17. GuruFocus rates BOM:530427 with a GF Score™ of 52/100. The stock has 8 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Choksi Asia ranks better than 80.74% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Choksi Asia's annualized net income for the quarter that ended in Mar. 2026 was ₹30.1 Mil. Choksi Asia's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹328.0 Mil. Therefore, Choksi Asia's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 9.17%.
The historical rank and industry rank for Choksi Asia's Return-on-Tangible-Equity or its related term are showing as below:
BOM:530427'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3.49 Med: 6.17 Max: 17.67
Current: 17.62
During the past 13 years, Choksi Asia's highest Return-on-Tangible-Equity was 17.67%. The lowest was -3.49%. And the median was 6.17%.
BOM:530427's Return-on-Tangible-Equity is ranked better than 80.74% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs BOM:530427: 17.62
Choksi Asia (BOM:530427) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Choksi Asia Return-on-Tangible-Equity Related Terms
Choksi Asia Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Choksi Asia's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530427 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Choksi Asia's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Choksi Asia Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Choksi Asia's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Choksi Asia's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.17% mean?
Choksi Asia (BOM:530427) has a Return-on-Tangible-Equity of 9.17% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Choksi Asia and its competitors. This is 49% above median its historical median of 6.17. According to the industry distribution chart, Choksi Asia ranks #146 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 19.3%.
Is Choksi Asia's Return-on-Tangible-Equity too high?
Choksi Asia's current Return-on-Tangible-Equity of 9.17% is 49% above median its 10-year median of 6.17. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Choksi Asia's value of 9.17% is 127.5% above this industry median. Based on the distribution chart, Choksi Asia ranks #146 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Choksi Asia has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Choksi Asia's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Choksi Asia ranks #146 out of 758 companies for Return-on-Tangible-Equity. This places Choksi Asia in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. Choksi Asia's value of 9.17% is 127.5% above this benchmark. While the company's 10-year median is 6.17 vs. the industry median of 4.03, Choksi Asia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Choksi Asia's current Return-on-Tangible-Equity of 9.17% is 127.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Choksi Asia and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Choksi Asia's current Return-on-Tangible-Equity is 9.17%, which is 49% above median its own 10-year median of 6.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Choksi Asia stock overvalued right now?
Choksi Asia (BOM:530427) has a current Return-on-Tangible-Equity of 9.17%. The current Return-on-Tangible-Equity is 9.17%, which is 49% above median its 10-year median of 6.17 and 127.5% above the Medical Devices & Instruments industry median of 4.03. Choksi Asia's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Choksi Asia (BOM:530427), the current Return-on-Tangible-Equity is 9.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Choksi Asia Ltd formerly Choksi Imaging Ltd is an India-based company engaged in the manufacturing of photosensitized materials, medical X-rays, and other healthcare products. The company sells and derives revenue from products like X-ray films, ultrasound, computed radiography systems, specialty X-ray films, etc. In addition, the company also offers maintenance services for X-ray processors, equipment, and computer radiography systems. The firm provides various photographic, and ultrasonic sound services in association with Protec, Medtron, and others.
52GF Score
Get the complete analysis for BOM:530427
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530427 has been successfully added to your 
